ArticleBMC nephrology2026
Bile acids as a predictor for all-cause mortality in peritoneal dialysis patients: a retrospective cohort study.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundBile acids (BAs) are now recognized as endocrine hormones involved in glucose and lipid metabolism regulation and inflammation control. Recent studies have also shown the association of BAs level in chronic kidney disease progression and hemodialysis patients' prognosis. However, their role in peritoneal dialysis (PD) is unknown. Therefore, based on a longitudinal cohort, this study aims to explore the relationship of BAs and all-cause mortality in PD patients.
methodsA retrospective cohort study was conducted involving 517 PD patients. Serum BAs level prior to PD catheterization were collected. Restricted cubic spline (RCS) analysis with full adjustment was used to characterize the dose-response relationship between serum BAs and all-cause mortality. Cox proportional hazards regression models were performed to assess the independent association between BAs levels and all-cause mortality.
resultsA total of 517 patients were included. During a median follow-up of 3.65 (1.36, 5.46) years, death occurred in 210 of 517 (40.6%) patients. The relationship between BAs levels and the risk of all-cause mortality was fitted using multivariate RCS adjusted for clinical relevant factors showing that BAs levels were linearly associated with all-cause mortality (p for non-linearity = 0.589). Further Kaplan-Meier survival analysis revealed a significantly higher all-cause mortality risk in the high BAs group (log rank score 13.04, p < 0.001). Cox regression showed that elevated BAs levels were an independent risk factor for all-cause mortality in PD patients (HR = 1.056, 95% CI: 1.005-1.109, p = 0.031) after adjusting for confounding factors.
conclusionElevated pre-dialysis serum BAs levels are independently associated with increased all-cause mortality in PD patients. Serum BAs may represent a potential prognostic indicator, although further validation is required before clinical application.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.